EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and outcomes of [177Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis

Martin Rust, David Ventura, Clemens Backhaus, Ole Platte, Benjamin Matheja, Michael Schäfers, Martin Bögemann, Lars Stegger, Wolfgang Roll, Kambiz Rahbar

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08060-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Martin Rust und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Münster, Münster, Germany. martin.rust@ukmuenster.de. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Prostatic Neoplasms, Castration-Resistant, Lutetium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Münster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose [ 177 Lu]Lu-PSMA-617 was approved after the VISION trial demonstrated significant benefit in metastatic castration-resistant prostate cancer (mCRPC). This study evaluated outcomes of [ 177 Lu]Lu-PSMA-617 with or without concurrent Androgen Receptor Pathway Inhibitors (ARPI) in a real-world setting.

Methods

We retrospectively analyzed electronic health records of mCRPC patients treated with [ 177 Lu]Lu-PSMA-617 in routine clinical practice between June 2023 and August 2024. Primary endpoints were overall survival (OS) and PSA50 response; secondary endpoints included PSA-progression-free survival (PSA-PFS), radiographic PFS (rPFS), and percentage PSA change from baseline. Baseline characteristics were compared using Mann–Whitney U and chi-square tests. Survival outcomes were evaluated using Kaplan–Meier and Cox regression analyses.

Results

Among 108 patients, 65 received [ 177 Lu]Lu-PSMA-617 monotherapy and 43 concurrent ARPI therapy. Baseline characteristics were generally well balanced, with slightly higher hemoglobin and a trend toward lower PSA in the ARPI group. No significant between-group differences were observed for median OS (12.7 vs. 13.5 months; p = 0.96), PSA50 response rate (51.2% vs. 52.3%; p = 0.91), PSA-PFS (6.3 vs. 6.2 months; p = 0.54), or median PSA change from baseline (−39.0% vs. −43.1%; p = 0.24). A non-significant trend in rPFS favored the ARPI group (10.6 vs. 9.8 months; p = 0.057). On multivariable Cox regression, concurrent ARPI use was not independently associated with OS (adjusted HR 1.29; p = 0.33).

Conclusion

In this real-world cohort of ARPI- and taxane-pretreated mCRPC patients, concurrent ARPI use during [ 177 Lu]Lu-PSMA-617 was not independently associated with improved clinical outcomes. These exploratory findings do not provide evidence to support routine continuation of ARPI beyond progression at the time of radioligand therapy initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantLutetiumReceptors, AndrogenHumansMaleRetrospective StudiesTreatment OutcomeAgedMiddle AgedRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

Castration-resistantOverall survivalProstate-specific antigenProstatic neoplasmsRadioligand therapy

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Receptors, AndrogenRadioisotopesPSMA-617lutetium (177Lu) vipivotide tetraxetanProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Münster, Münster, Germany. martin.rust@ukmuenster.de.
  • West German Cancer Center, Münster, Germany. martin.rust@ukmuenster.de.
  • Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
  • West German Cancer Center, Münster, Germany.
  • Department of Urology, University Hospital Münster, Münster, Germany.

Förderung

  • Universitätsklinikum Münster

Zitieren

APA

Rust, M., Ventura, D., Backhaus, C., Platte, O., Matheja, B., Schäfers, M., Bögemann, M., Stegger, L., Roll, W., & Rahbar, K. (2026). Efficacy and outcomes of [177Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08060-5

Vancouver

Rust M, Ventura D, Backhaus C, Platte O, Matheja B, Schäfers M, et al. Efficacy and outcomes of [177Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08060-5

BibTeX
@article{Rust2026,
  author = {Rust, Martin and Ventura, David and Backhaus, Clemens and Platte, Ole and Matheja, Benjamin and Schäfers, Michael and Bögemann, Martin and Stegger, Lars and Roll, Wolfgang and Rahbar, Kambiz},
  title = {Efficacy and outcomes of [177Lu]Lu-PSMA-617 in patients with mCRPC treated with or without concurrent ARPI: a real-world single-center analysis},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08060-5}
}
Kostenlos starten →